Umoja_Biopharma_Logo.png
Umoja Biopharma Announces Oral and Poster Presentations at the 66th American Society of Hematology Annual Meeting
November 05, 2024 09:05 ET | Umoja Biopharma, Inc.
SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja_Biopharma_Logo.png
Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
October 04, 2024 09:05 ET | Umoja Biopharma, Inc.
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja_Biopharma_Logo.png
Umoja Biopharma Announces Oral Presentation at the American College of Rheumatology Convergence 2024
September 30, 2024 16:30 ET | Umoja Biopharma, Inc.
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja_Biopharma_Logo.png
Umoja Biopharma to Present at the 9th Annual CAR-TCR Summit
September 11, 2024 16:30 ET | Umoja Biopharma, Inc.
SEATTLE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja_Biopharma_Logo.png
Umoja Biopharma to Participate in Upcoming Investor Conferences in September
August 29, 2024 16:30 ET | Umoja Biopharma, Inc.
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja_Biopharma_Logo.png
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
July 31, 2024 07:00 ET | Umoja Biopharma, Inc.
- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by...
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
June 13, 2024 08:00 ET | Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
Umjola.jpg
Umoja Biopharma to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 19, 2024 08:30 ET | Umoja Biopharma, Inc.
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
2024-02-28 -- Umoja -- Britton Russell New CFO -- Photo
Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer
February 28, 2024 08:30 ET | Umoja Biopharma, Inc.
SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umjola.jpg
Umoja Biopharma to Participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference
February 22, 2024 08:30 ET | Umoja Biopharma, Inc.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...